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Limitations of these studies include failure to control for important confounders, small 
sample size and short study period, which may have impact on the risk of cancer. 
CONCLUSIONS: Given the fact that cancers are rare and often take a long time to 
develop, further studies require very large population with long follow up time to have 
sufﬁcient power to detect a possible effect. This, combined with small proportion of 
insulin users who were exposed to glargine, may be a reason to studies that found no 
association, which leaves a question of a class effect. Future studies to explore the 
effect of all other insulins and the possible mechanism may help to untangle this 
question.
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ADJUVANT BREAST CANCER (BC)
Burke JP1, Seal B2, Teitelbaum A3, Henk HJ1
1i3 Innovus, Eden Prairie, MN, USA, 2Sanoﬁ-Aventis Pharmaceuticals, Bridgewater, NJ, USA, 
3i3 Global, San Diego, CA, USA
OBJECTIVES: Neuropathy, a common side effect of taxanes, is often dose-limiting 
and may result in changes in treatment. This study examined the occurrence of neu-
ropathy in claims data from commercially insured US patients with BC treated with 
adjuvant DC or PC. METHODS: This retrospective database analysis used eligibility, 
medical and pharmacy claims data from a large US health care organization, including 
subjects with a claim for BC and a claim for DC or PC-containing chemotherapy from 
1/1/98–12/31/05. Subjects were stratiﬁed by dosing interval (weekly (qw) or Q 21 days 
(q3w)). Neuropathy was deﬁned using ICD-9-CM codes 356.4, 356.8, 356.9, 357.2, 
357.4, 357.5, 357.6, 357.7, 357.8x, 357.9, 377.34, 354.4, 354.5, 354.8, 354.9, 
355.7x, 355.8 and 355.9. Neuropathy grade could not be assessed by claims data. 
Subjects were followed until the earliest of date of death or last enrollment or 
12/31/06. Chi-square was used to compare descriptive variables. Logistic regression 
(LR) was used to examine the independent association of index medication and 
neuropathy. Covariates included age, geographic region, baseline co-morbidity score 
and use of medications for neuropathy. RESULTS: A total of 3619 subjects were 
identiﬁed for PC (n = 329, qw; 1685, q3w) or DC (n = 204, qw; 1045, q3w). A sig-
niﬁcantly lower frequency of neuropathy was seen in the follow-up period for DC-
based treatments compared to PC (7.0% vs 10.6%, p < 0.001). Differences were also 
noted when stratifying by dosing interval (6.7% vs 10.0%; p = 0.003 in q3w, 9.3% 
vs 13.7%; p = 0.061 in qw). After adjusting for covariates, the odds of neuropathy 
remained signiﬁcantly lower with DC-based treatment (OR = 0.70, CI = 0.559, 0.920; 
p = 0.010). CONCLUSIONS: Less neuropathy was noted with DC-based treatment 
compared to PC. This difference persisted with stratiﬁcation by dosing interval. The 
lower occurrence of neuropathy with DC may favor maintenance of dose intensity.
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OBJECTIVES: Traditional methods for identifying comorbidities in retrospective 
observational research have relied primarily on claims data. The purpose of this study 
was to validate a 2-phased strategy to search EMR data to identify comorbidities 
among cancer patients. METHODS: Advanced stage NSCLC patients (N = 2513) who 
received chemotherapy from July 1, 2006–June 30, 2008 were identiﬁed using 
iKnowMed, US Oncology’s proprietary oncology-speciﬁc EMR system. EMR data 
were searched for documentation of the following comorbidities: moderate/severe 
renal disease, congestive heart failure (CHF), dementia, chronic obstructive pulmonary 
disease (COPD), cerebrovascular disease, paralysis, diabetes, peripheral vascular 
disease (PVD), myocardial infarction (MI), liver disease, and AIDS. The search was 
conducted in 2 phases. Initially, a series of programmatic queries were conducted to 
search standardized information on concomitant illnesses, patient history, review of 
systems, and diagnoses other than cancer. In a second phase, keyword searches of 
text-based ﬁelds (i.e., physician dictation notes, problem lists, etc.) were conducted. 
To evaluate the validity of the comorbidity information derived from the EMR, we 
randomly sampled 450 patients for whom we found no documentation of comorbidi-
ties using our 2-phased approach. We then exhaustively scanned available claims data 
and conducted comprehensive chart reviews to conﬁrm that these patients did not 
have any of the comorbidities of interest. Negative predictive values (true negatives / 
(true negatives + false negatives) were calculated. RESULTS: Using our 2-phased 
search of the EMR, we found an overall prevalence of comorbidities of 22%. The 
most commonly identiﬁed conditions were COPD, diabetes, PVD, and CHF. Among 
the random sample of 450 patients for whom no comorbidities were identiﬁed, we 
identiﬁed 36 who had evidence of comorbidities after scanning claims data and con-
ducting chart reviews (negative predictive value = 0.92). CONCLUSIONS: Results of 
this study suggest that efﬁcient queries of EMR data may provide reliable data on 
comorbid conditions among cancer patients.
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OBJECTIVES: Fludarabine (F) has been proven to be highly effective in the treatment 
of chronic lymphocytic leukemia (CLL). Both oral and IV F are used internationally. 
Recently, the oral formulation of ﬂudarabine was approved in the US for treating 
CLL, which may offer advantages for providers, payers and patients. This study is a 
systematic review of clinical trial and retrospective data for oral and IV ﬂudarabine, 
focusing on differences in efﬁcacy, complications, resource utilization, cost and patient 
preference. METHODS: PubMed and manual bibliographic searches were conducted 
to identify relevant publications for oral and IV F. Studies were included if they were: 
1) published after January 1, 2000, 2) derived from human subjects, 3) written or 
translated in English 4) focused on CLL, and 5) evaluated efﬁcacy, resource utilization, 
complications, costs or patient preference. RESULTS: There were 17 articles that met 
inclusion criteria. Results indicated that the pharmacokinetic proﬁle of oral and IV F 
were similar, with 25 mg/m2 of IV being equivalent to 40 mg/m2 of oral. Oral F has 
similar efﬁcacy and safety to IV F, and eliminates infusion related adverse events and 
administration costs. Studies indicated that providing oral F was more convenient for 
patients and nurses due to the absence of IV administration. No cost or pharmaco-
economic data were found. CONCLUSIONS: Oral and IV F were found to have 
similar clinical efﬁcacy and safety. The oral formulation may potentially lead to 
substantial economic beneﬁts when factoring in possible reductions in infusion related 
administration and adverse events. Future studies need to compare real-world clinical 
outcomes and economic impact of oral vs. IV F, taking into account decision-making 
in clinical practice of both health care providers and patients.
PCN8
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OBJECTIVES: To explore the impact of step therapy policies requiring the use of a 
1st-generation 5-hydroxytryptamine- receptor antagonist (5-HT3-RA) treatment 
before palonosetron (a 2nd generation 5-HT3-RA) on the incremental risk of chemo-
therapy induced nausea and vomiting (CINV) associated with a hospital or emergency 
room (ER) event. METHODS: Claims data (PharMetrics) were used to identify con-
tinuously enrolled adult patients diagnosed with breast cancer (BC) and initiated on 
cyclophosphamide-based chemotherapy (CT) within 4 months post-diagnosis or with 
lung cancer (LC) and initiated on carboplatin-based CT. Patients were stratiﬁed into 
those initiated and maintained on palonosetron throughout CT (Group 1) versus those 
treated on day 1/cycle 1 with any other 5-HT3-RA regimen (Group 2). Risks and 
frequency for CINV-associated hospital or ER events identiﬁed through ICD-9-CM 
codes for nausea, vomiting, and/or dehydration during a 6-month follow-up period 
were estimated using logistic and Poisson regression models, controlling for age, 
gender (LC only), comorbidity, and CT days. RESULTS: Of 3606 BC and 4497 LC 
identiﬁed patients, 1864 BC (52%) and 1806 LC (40%) initiated palonosetron. 
Groups 1 and 2 had comparable comorbidity and CT treatment days. Compared to 
group 2 patients, group 1 patients had a signiﬁcantly lower probability of CINV-
associated hospital or ER events (3.5% vs. 5.5% in BC and 9.5% vs. 12.8% in LC), 
had 47.4% (BC) and 29.1% (LC) fewer hospital or ER days with CINV, and fewer 
5-HT3-RA claims (mean ± SD 6.2 ± 3.3 vs. 7.9 ± 4.1 in BC and 7.7 ± 4.9 vs. 10.3 ± 
6.4 in LC), all at p < 0.05. Risk for CINV was 38% (BC) and 29% (LC) lower for 
group 1 patients (Odds Ratio = 0.62 in BC and 0.71 in LC, p < 0.05). CONCLU-
SIONS: LC or BC patients initiated and maintained on palonosetron throughout CT 
were at signiﬁcantly lower risk for costly CINV versus those on any other 5-HT3-RA 
on day 1/cycle 1 of CT treatment.
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BACKGROUND Randomized clinical trials remain the gold standard in evaluating 
different drug therapies on outcomes but are resource intensive. Retrospective studies 
using observational data are inexpensive but prone to selection bias due to non-ran-
dom differences between the intervention and comparator groups. The Propensity 
Score (PS) method is a novel, multivariate adjustment procedure that reduces con-
founding and selection bias. METHODS: This case-control study used the Health 
Facts® database (Cerner Corporation, Kansas City, MO), which integrates patient 
information from hospitals throughout the United States. Cancer patients receiving 
rasburicase or allopurinol were eligible for study inclusion. Both drugs reduce uric 
acid (UA) elevation otherwise resulting from tumor lysis syndrome. The PS is the 
Abstracts A25
probability of receiving rasburicase and is calculated from a non-parse logistic regres-
sion model that is adjusted for age, demographics, lab tests, ICU admission, Charlson 
Comorbidity Index, hospital characteristics, and other factors. Each rasburicase 
patient’s PS is matched via a 5:1 digit Greedy algorithm to that of an allopurinol 
patient to reduce confounding. Alternatively, the PS is added as another predictor in 
a non-parse Generalized Linear Model when estimating the effect of rasburicase on 
outcomes. RESULTS: Of 8,257 patients, 71 rasburicase patients met our inclusion 
criteria and were matched to 71 allopurinol patients. Before matching, the median 
[25th, 75th percentile] total costs of rasburicase patients vs. allopurinol patients were 
$30,681 [$17,259, $58,241] vs. $18,106 [$8,937, $39,084]. After initial matching, 
median costs were lower with rasburicase: only $30,681, vs. $58,438 (P = 0.007), 
while pre-Rx minus post-Rx mean UA differences were signiﬁcantly greater with 
rasburicase vs allopurinol (9.3 vs. 0.9 mg/dL, P < 0.001). CONCLUSIONS: Multivari-
ate PS adjustment reduces selection bias and confounding when quantifying treatment 
effects of drug therapies. A preliminary PS analysis demonstrated that rasburicase 
was associated with greater UA reduction than allopurinol, as well as lower medical 
care costs.
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OBJECTIVES: Examine the effectiveness of using prophylactic G-CSF among NHL 
patients treated with anthracycline-based chemotherapy in practice. METHODS: 
Using the national Surveillance, Epidemiology and End Results (SEER)-Medicare 
linked database, we studied patients 66 years or older diagnosed as NHL and on 
anthracycline in one of the 13 SEER registry areas from 1994–2002. Prophylactic 
G-CSF use was designated if a patient had a G-CSF claim within the ﬁrst 5 days of 
the ﬁrst chemotherapy cycle. Neutropenia hospitalization (NH) was identiﬁed within 
6 months of diagnosis. Multiple regression estimates were used to examine whether 
treated patients actually beneﬁted. Instrumental variable estimates using local area 
prophylactic G-CSF treatment rates as instruments were used to estimate whether 
increases in the G-CSF utilization rate could lead to further reductions in the rate of 
neutropenic hospitalization. RESULTS: Only 9.83% of study patients had early 
G-CSF. After adjustment for patient demographic and clinical risk factors, multiple 
regressions indicated prophylactic G-CSF signiﬁcantly reduced NH events for the 
patients who received G-CSF (OR = 0.54, 95% CI = 0.34–0.87). Chow F-statistics 
showed our instrumental variable described a statistically signiﬁcant portion in the 
variation in G-CSF use (F = 14.65, P = 0.0001). Our instrumental variable estimates 
were not statistically signiﬁcant from zero. CONCLUSIONS: Among elderly NHL 
patients on anthracycline-based chemotherapy, our multiple regression estimates 
suggest that prophylactic G-CSF treated patients reduced their neutropenia risk. 
However, our instrumental variable results suggest that expanding prophylactic 
G-CSF use rates will not signiﬁcantly reduce NH rates. These results suggest that 
providers optimally sorted the use of G-CSF patients to those patients that are most 
apt to gain.
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BACKGROUND: Retrospective observational studies are often the only practical way 
to assess drug effects on uncommon diagnoses. However, because treatment assign-
ment is not randomized, selection bias and confounding can distort the effect esti-
mates. A new multivariate statistical method based on the Propensity Score (PS) of 
receiving treatment minimizes this bias. METHODS: This case-control study used the 
Health Facts® database (Cerner Corporation; Kansas City, MO), which integrates 
patient information from hospitals throughout the United States. Cancer patients 
receiving rasburicase or a combination of rasburicase and allopurinol were eligible for 
study inclusion. Both therapies reduce uric acid (UA) elevation otherwise resulting 
from tumor lysis syndrome. The PS is the probability of receiving rasburicase and is 
calculated from a non-parse logistic regression model that adjusts for age, demograph-
ics, lab tests, ICU admission, Charlson Comorbidity Index, hospital characteristics, 
and other factors. Each rasburicase patient’s PS was matched via a 5:1 digit Greedy 
algorithm to that of a Combination patient. Alternatively, the PS was added as another 
predictor in a non-parse Generalized Linear Model when estimating the effect of 
rasburicase on outcomes. RESULTS: Of 71 rasburicase and 123 combination patients, 
47 matched pairs were created. Differences in confounders by group were non-signif-
icant after matching. Before matching, the median [25th, 75th percentile] total costs of 
rasburicase patients vs. combination patients were $30,681 [$17,259, $58,241] vs. 
$54,862 [$25,907, $108,454]. After initial matching, rasburicase patients had lower 
median costs ($32,831 vs. $73,226; P = 0.02) and greater pre-Rx (baseline) minus 
post-Rx mean differences in UA levels (9.0 vs. 2.5 mg/dL; P = 0.004). CONCLU-
SIONS: Multivariate PS adjustment reduces confounding when quantifying treatment 
effects of drug therapies. A preliminary PS analysis demonstrated that rasburicase 
monotherapy was associated with greater UA reduction than rasburicase-allopurinol 
combination, when either is administered in the context of TLS management in a 
“real-world” clinical setting.
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OBJECTIVES: The Center for Comparative Effectiveness Research in Cancer Genom-
ics (CANCERGEN) is a multi-disciplinary, national consortium established with the 
aim of generating high-quality evidence on the clinical utility and economic value of 
Genomics and Personalized Medicine (GPM) applications. This type of effort requires 
horizon scaning to identify promising candidates for evaluation in a randomized 
controlled trial (RCT). METHODS: A search of the peer-reviewed literature was 
performed using MEDLINE. Keywords included terms likely to be included in studies 
reporting the results of genomic-based prognostication and prediction for cancer. 
References were restricted to the last ﬁve years to identify technologies sufﬁciently 
developed to be appropriate for study in a RCT. The search was restricted to the ﬁve 
cancers with the highest prevalence and to key clinical journals (Abridged Index 
Medicus), as the unrestricted literature would identify targets too early in the develop-
ment cycle for a RCT. The peer-reviewed literature was supplemented by searching 
the “grey” literature including major conferences in cancer for the last two years, 
allowing for inclusion of technologies which have not entered the peer-reviewed litera-
ture. The results were further analyzed for relevance using criteria such as: the title/
abstract containing reference to a new/existing genetic test, biomarkers or gene targets 
relevant to cancer prognostication and/or effectiveness of existing/potential adjuvant 
therapy. RESULTS: In the peer-reviewed literature, our search strategy indicated 199 
references matching our keyword search and restrictions. After application of criteria 
above, the list was reduced to 71 candidates. As an example of the “grey” literature 
search, 42 additional results were obtained from a search of the San Antonio Breast 
Cancer Conference (2008). CONCLUSIONS: A horizon scanning study is needed to 
identify genetic-based technologies for cancer, for which CER can be performed in a 
RCT. The results from this horizon-scan will drive development of new GPM trial 
designs incorporating CER.
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OBJECTIVES: A randomized trial comparing doxetaxel (D) and paclitaxel (P) treated 
patients has shown greater neurologic toxicity with P given weekly. This study aimed 
to compare neuropathy (NP) and NP-related outcomes between D and P in a com-
munity practice. METHODS: The analysis was conducted using the Georgia Cancer 
Specialist Database (2003–2008) supplemented by chart abstraction. Patients with 
stage I-III breast cancer (BC) and treated with adjuvant D or P-containing chemo-
therapy (CT) were followed from initial treatment to the earliest of death, loss to 
follow-up, or switch to other regimens. NP and NP-related outcomes were measured 
as (1) 6-month rate of severe NP (CTC grade 3/4), (2) 6-month rate of receiving NP-
related medications (NPMs), (3) proportion of patients whose CT was affected due 
to NP (CT being held, discontinued, or dose reduction). Univariate and multivariate 
analyses with adjustment of clinical and demographic characteristics were performed 
to compare the outcomes between D and P groups. RESULTS: A total of 591 (63.6%) 
and 338 patients treated with D and P were included. The univariate analyses showed 
that P had higher rates of severe NP (4.9% vs. 1.0%) and NPMs use (28.1% vs. 7.6%) 
within 6 months, and their CT was more likely to be affected (7.1% vs. 1.5%), 
compared with D group (all p < 0.001). Similarly, the adjusted results (all p < 0.001) 
showed that P was at higher risks for severe NP (HR = 3.50), NPMs use (HR = 6.40), 
and CT interruption (OR = 5.40). CONCLUSIONS: This study found that P was 
associated with higher risks for severe NP and CT interruption, compared to D. The 
ﬁndings are consistent with published trials and call for close observation of NP when 
using P. The results should also be viewed in the context that NP poses higher eco-
nomic burden over non-NP patients. The ﬁndings need to be conﬁrmed by addition 
studies from community settings.
